Innovation Dashboard - Discussion Forum

Start New Topic

Next-IO™ Anti-KIR2DL4 Monoclonal Antibody Program

The focus of cancer immunotherapies is, by leveraging the immune system, to utilize the natural immunity to fight with cancer. Compared with traditional therapies, monoclonal antibody-based immunotherapy is thought to be more advantageous. As a thriving CRO, Creative Biolabs Next-IO™ team is dedicated to developing and accelerating novel therapeutic mAb programs with the hope of our partners. This anti-KIR2DL4 mAb program aims to develop therapeutic mAb against KIR2DL4 that could potentially restore the cytotoxicity activity of NK cells. Learn more: Next-IO™ Anti-KIR2DL4 Monoclonal Antibody Program

Posted on : Thu, Oct 31, 2024 3:14 AM

Posted By : Catalina Garcia